Search Within

Alison Michele Schram

Formats
  1. Meeting Abstract (58)
  2. Journal Article (57)
  3. Editorial (3)
  4. Review (3)
  5. Miscellaneous (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (124)
  2. Early Drug Development Service (124)
  3. Gynecologic Medicine Service (124)
  4. Solid Tumor Oncology Division (124)
  5. GSK Faculty (53)
  6. Thoracic Oncology (50)

More Groups

People
  1. David Hyman (49)
  2. Alexander Drilon (46)
  3. Michael Berger (23)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Helen Won (14)

More People

Years
  1. 2025 (6)
  2. 2024 (18)
  3. 2023 (9)
  4. 2022 (16)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Annals of Oncology (13)
  3. Cancer Research (13)
  4. Cancer Discovery (9)
  5. Clinical Cancer Research (5)
  6. JCO Precision Oncology (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. American Association for Cancer Research (30)
  3. Oxford University Press (14)
  4. Nature Publishing Group (12)
  5. Elsevier Inc. (10)
  6. American Medical Association (3)

More Publishers

Results (124)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors
    Meeting Abstract

    Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator
    Journal Article

    Puzio-Kuter, A. M.; Xu, L.; McBrayer, M. K.; Dominique, R.; Li, H. H.; Fahr, B. J.; Brown, A. M.; Wiebesiek, A. E.; Russo, B. M.; Mulligan, C. L.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • PYNNACLE phase II assessing rezatapopt in patients with advanced solid tumors, including lung cancer, harboring a TP53 Y220C mutation
    Meeting Abstract

    De Miguel, M. J.; Dumbrava, E. E.; Body, A.; Eberst, L.; Frenel, J. S.; Italiano, A.; Johnson, M. L.; Kaczmar, J.; Kummar, S.; Lorusso, P. M.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors
    Journal Article

    Rao, M.; Merrill, M.; Troxel, M.; Chiang, S.; Momeni-Boroujeni, A.; Hensley, M. L.; Schram, A. M.
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Efficacy of zenocutuzumab in NRG1 fusion-positive cancer
    Journal Article

    Schram, A. M.; Goto, K.; Kim, D. W.; Macarulla, T.; Hollebecque, A.; O'Reilly, E. M.; Ou, S. H. I.; Rodon, J.; Rha, S. Y.; Nishino, K.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
    Meeting Abstract

    Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation
    Meeting Abstract

    Schram, A.; Shapiro, G.; Thompson, J.; Vandross, A.; Kummar, S.; El-Khoueiry, A.; LeDuke, K.; Fellous, M.; Alland, L.; Dumbrava, E.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Meeting Abstract

    Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Meeting Abstract

    Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save